Study Reveals Medication Non-Adherence Persists

Twenty-four percent of patients given a new medication by their physician did not fill the prescription, according to a new study by researchers at Harvard University, Brigham and Women’s Hospital and CVS Caremark.

Advertisement

For their study, researchers evaluated more than 423,000 e-prescriptions written in 2008 by 3,634 doctors for more than 280,000 patients. The team matched the e-prescriptions with resulting claims data, or in the case of those not filling the prescription, used the lack of a claim within six months to identify primary non-adherence.

 

Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!

Researchers outlined the following key findings from their study:

•    Patients who received prescriptions for medications that were not included on their healthcare formulary — and were therefore more expensive because co-pays would be higher — are more likely not to fill their first prescription.
•    The researchers determined that patients who live in higher income areas are more likely to fill prescriptions for new medications.
•    Prescriptions written for infants are almost always filled, and antibiotics are filled at a rate of 90 percent.
•    Medications for hypertension or diabetes saw primary non-adherence rates in excess of 25 percent.

Related Articles on Medication Safety:

5 Steps to Develop an Outstanding ASC Quality Program
U Illinois in Chicago Granted $4.25M to Develop Programs for Safer Medication Use
FDA: Safety Labeling Changes Made to Prescribing Information for 34 Products in September

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.